Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with nonsmall cell lung cancer: Correlation with survival after erlotinib and gefitinib treatment

ecancermedicalscience

Volumn 4, Issue 1, 2010, Pages

  Kappers, I ^a   Vollebergh, M A ^a   Van Tinteren, H ^a   Korse, C M ^a   Nieuwenhuis, L L ^a   Bonfrer, J M G ^a   Klomp, H M ^a   Van Zandwijk, N ^a   Van Den Heuvel, M M ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADULT; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; SMOKING;

EID: 80054743518     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2010.178     Document Type: Article

References (46)

1. Veale D, Ashcroft T, Marsh C, Gibson GJ and Harris AL (1987) Epidermal growth factor receptors in non-small cell lung cancer Br J Cancer 55 513-6 PMID: 3038157 (Pubitemid 17098858)
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J (15-6-2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237-46 PMID: 12748244 doi:10.1200/JCO. 2003.10.038
3. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC (22-10-2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149-58 PMID: 14570950 doi:10.1001/jama.290.16.2149
4. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P and Bonomi P (15-8-2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238-47 PMID: 15310767 doi:10.1200/JCO.2004.11.057
5. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J (15-6-2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237-46 PMID: 12748244 doi:10.1200/JCO. 2003.10.038
6. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC (22-10-2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149-58 PMID: 14570950 doi:10.1001/jama.290.16.2149
7. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben Porat L, Memoli N, Zakowski M, Rusch V and Heelan RT (15-3-2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 1103-9 PMID: 15020612 doi:10.1200/JCO.2004.08.158
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L (14-7-2005) Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-32 PMID: 16014882 doi:10.1056/NEJMoa050753
9. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K (29-10-2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527-37 PMID: 16257339 doi:10.1016/S0140-6736(05)67625-8
10. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y and Nukiwa T (20-7-2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 3340-6 PMID: 16785471 doi:10.1200/JCO.2005.05.4692
11. Janne PA, Engelman JA and Johnson BE (10-5-2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 3227-34 PMID: 15886310 doi:10.1200/JCO.2005.09. 985
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA (20-5-2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 2129-39 PMID: 15118073 doi:10.1056/NEJMoa040938
13. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M (4-6-2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-500 PMID: 15118125 doi:10.1126/science.1099314
14. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H (7-9-2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 13306-11 PMID: 15329413 doi:10.1073/pnas.0405220101
15. van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S and Nederlof P (2007) EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer Ann Oncol 18 99-103 PMID: 17060486 doi:10.1093/annonc/mdl323
16. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Jr. and Varella-Garcia M (4-5-2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643-55 PMID: 15870435
17. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA (14-7-2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 133-44. PMID: 16014883 doi:10.1056/NEJMoa050736
18. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N and Holloway B (1-11-2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 5034-42 PMID: 17075123 doi:10.1200/JCO.2006.06.3958
19. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC and Maihle NJ (1999) Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 8 129-37 PMID: 10067810 (Pubitemid 29085379)
20. Carney WP, Burrell M, Morris LD and Hamer PJ (2002) Normal levels of serum EGFr and decreases in several cancers Proceedings AACR Vol 43, Abstract #240
21. Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, Yi SY, Shim KS and Han WS (15-5-1997) Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients Cancer 79 1879-83 PMID: 9149012 doi:10.1002/(SICI) 1097-0142(19970515)79:10〈1879::AIDCNCR6〉3.3.CO;2-R
22. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP and Brandt-Rauf PW (1994) The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients J Occup Med 36 1324-8 PMID: 7884573 doi:10.1097/00043764-199412000- 00013
23. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crino L, Tonato M and Villa E (15-9-2004) Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer Clin Cancer Res 10 6006-12 PMID: 15447984 doi:10.1158/1078- 0432.CCR-03-0770
24. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crino L, Tonato M and Villa E (15-9-2004) Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer Clin Cancer Res 10 6006-12 PMID: 15447984 doi:10.1158/1078- 0432.CCR-03-0770
25. Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H and Ichinose Y (2005) Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer Eur J Cancer 41 1286-90 PMID: 15939264 doi:10.1016/j.ejca.2005.03.011
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM (22-8-2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93 387-91 PMID: 16106245 doi:10.1038/sj.bjc.6602678
27. Carney WP, Burrell M, Morris LD and Hamer PJ (2002) Normal levels of serum EGFr and decreases in several cancers Proceedings AACR Vol 43, Abstract #240
28. Molina R, Bonfrer J, Banfi G, Bugugnani MJ, Cornu F, Hannemann-Pohl K, Hubl W, Merz O, Bach M and Mack M (2000) External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser Clin Lab 46 169-79 PMID: 10791126 (Pubitemid 30162779)
29. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model Biometrika 69 239-41 doi:10.1093/biomet/69.1.239
30. Therneau TM, Grambsch PM and Fleming TR (1990) Martingale-based residuals and survival models. Biometrika 77 147-60 doi:10.1093/biomet/77.1.147
31. Albain KS, Swann RS and Rusch VR et al. (2005) Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup trial 0139 (RTOG 9309). J Clin Oncol 23
32. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, Splinter TA and Giaccone G (21-3-2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 99 442-50 PMID: 17374834
33. Van Schil P, van Meerbeeck J, Kramer G, Splinter T, Legrand C, Giaccone G, Manegold C and van Zandwijk N (2005) Morbidity and mortality in the surgery arm of EORTC 08941 trial Eur Respir J 26 192-7 PMID: 16055865 doi:10.1183/09031936.05.00127204
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG (2-2-2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-16 PMID: 10655437 doi:10.1093/jnci/92.3.205
35. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K and Stanners CP (21-4-1989) Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule Cell 57 327-34 PMID: 2702691 doi:10.1016/0092-8674(89)90970-7
36. Ordonez C, Screaton RA, Ilantzis C and Stanners CP (1-7- 2000) Human carcinoembryonic antigen functions as a general inhibitor of anoikis Cancer Res 60 3419-24 PMID: 10910050 (Pubitemid 30482158)
37. Screaton RA, Penn LZ and Stanners CP (1997) Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation J Cell Biol %19 137 939-52 PMID: 9151695 doi:10.1083/jcb.137.4.939
38. Stanners CP (1998) Contributions of the human CEA family to malignant transformation in Stanners CP (ed): Cell Adhesion and Communication Mediated by the CEA Family: Basic and Clinical Perspectives. Amsterdam: Harwood Academic Publishers vol 5, pp 141-54
39. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 67-81 PMID: 10202129 doi:10.1006/scbi.1998.0119
40. Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H and Ichinose Y (2005) Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer Eur J Cancer 41 1286-90 PMID: 15939264doi:10.1016/j.ejca.2005.03.011
41. Concannon JP, Dalbow MH, Hodgson SE, Headings JJ, Markopoulos E, Mitchell J, Cushing WJ and Liebler GA (1978) Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma Cancer 42 1477-83 PMID: 709518 doi:10.1002/1097-0142(197809)42: 3+〈1477::AID-CNCR2820420818〉3.0.CO;2-E
42. Carney WP, Burrell M, Morris LD and Hamer PJ (2002) Normal levels of serum EGFr and decreases in several cancers Proceedings AACR Vol 43 Abstract #240
43. Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C and Paez de la Cadena M (21-5-2007) Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma Br J Cancer 96 1569-78 PMID: 17453000 doi:10.1038/sj.bjc.6603770
44. Jacot W, Pujol JL, Boher JM and Lamy PJ (2-8-2004) Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer Br J Cancer 91 430-3 PMID: 15226769 doi:10.1038/sj.bjc.6601987
45. Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B and Woitowitz HJ (1999) p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer Br J Cancer 80 1987-94 PMID: 10471051 doi:10.1038/sj.bjc.6690632
46. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crino L, Tonato M and Villa E (15-9-2004) Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer Clin Cancer Res 10 6006-12 PMID: 15447984 doi:10.1158/1078- 0432.CCR-03-0770